MicroStrategy
MSTR
NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
US Stock MarketDetailed Quotes
TLX Telix Pharmaceuticals
- 15.820
- -0.520-3.18%
Close Dec 20 16:00 ET
5.30BMarket Cap181.84P/E (TTM)
17.570High15.600Low10.46KVolume16.000Open16.340Pre Close168.37KTurnover0.06%Turnover Ratio1757.78P/E (Static)334.72MShares19.99052wk High22.06P/B268.94MFloat Cap14.44052wk Low--Dividend TTM17.00MShs Float19.990Historical High--Div YieldTTM12.06%Amplitude14.440Historical Low16.091Avg Price1Lot Size
About Telix Pharmaceuticals Company
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Company Profile
SymbolTLX
Company NameTelix Pharmaceuticals
Founded2017
CEODr. Christian Behrenbruch, D.Phil.,J.D.
MarketNASDAQ
Employees234
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
Address55 Flemington Road,Suite 401,North Melbourne
CityMelbourne
ProvinceVictoria (VIC)
CountryAustralia
Zip Code3051
Phone61-3-9093-3855
Websitehttp://www.telixpharma.com
Company Executives
- Name
- Position
- Salary
- Dr. Christian Behrenbruch, D.Phil.,J.D.
- Director, Managing Director and Group Chief Executive Officer
- --
- David Cade
- Group Chief Medical Officer
- --
- Darren Smith
- Group Chief Financial Officer
- --
- Darren Patti
- Group Chief Operating Officer
- --
- H. Kevin McCann, A.O.,B.A.,L.L.M.
- Non-Executive Chairman of the Board
- --
- Tiffany P. Olson, M.B.A.
- Independent Director
- --
- Jann Skinner, B.Com,F.C.A.
- Independent Director
- --
- Dr. Mark Nelson, M.Phil,PhD
- Independent Director
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
